Broncus HoldingBRNHF 39 OCF Margin % is 354.67% as of Dec. 2025. GuruFocus rates BRNHF with a GF Score™ of 39/100. The stock has 7 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Broncus Holding ranks worse than 97.79% on this metric.
The historical rank and industry rank for Broncus Holding's OCF Margin % or its related term are showing as below:
BRNHF'
s OCF Margin % Range Over the Past 10 Years
Min: -5737.37 Med: -289.17 Max: -123.01
Current: -5737.93
During the past 7 years, the highest OCF Margin % of Broncus Holding was -123.01%. The lowest was -5737.37%. And the median was -289.17%.
BRNHF's OCF Margin % is ranked worse than 97.79% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 5.86
vs BRNHF: -5737.93
Broncus Holding OCF Margin % Related Terms
Broncus Holding OCF Margin % Historical Data
* Premium members only.
The historical data trend for Broncus Holding's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Broncus Holding's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Broncus Holding OCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Broncus Holding's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Broncus Holding's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Broncus Holding (BRNHF) has a OCF Margin % of 354.67% as of Dec. 2025. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Broncus Holding and its competitors. According to the industry distribution chart, Broncus Holding ranks #797 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 97.8%.
Is Broncus Holding's OCF Margin % too high?
Broncus Holding's current OCF Margin % is 354.67%. The Medical Devices & Instruments industry median OCF Margin % is 5.86. Broncus Holding's value of 354.67% is 5952.4% above this industry median. Based on the distribution chart, Broncus Holding ranks #797 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Broncus Holding has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Broncus Holding's OCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Broncus Holding ranks #797 out of 815 companies for OCF Margin %. This places Broncus Holding in the lower half of its industry. The industry median OCF Margin % is 5.86. Broncus Holding's value of 354.67% is 5952.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Medical Devices & Instruments company?
The median OCF Margin % among Medical Devices & Instruments companies is 5.86, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Broncus Holding's current OCF Margin % of 354.67% is 5952.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Broncus Holding and its competitors. For the Medical Devices & Instruments industry, the median OCF Margin % is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Broncus Holding's current OCF Margin % is 354.67%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Broncus Holding stock overvalued right now?
Broncus Holding (BRNHF) has a current OCF Margin % of 354.67%. The current OCF Margin % is 354.67% and 5952.4% above the Medical Devices & Instruments industry median of 5.86. Broncus Holding's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Broncus Holding (BRNHF), the current OCF Margin % is 354.67% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Broncus Holding Corp is focused on provision of interventional treatment of Chronic Obstructive Pulmonary Disease and lung cancer. It engages in the field of Interventional Pulmonology, providing solutions for lung diseases in China and globally. Its products portfolio includes the InterVapor Thermal Vapor Treatment System the only implantable medical device to treat COPD; BroncAblate Radiofrequency Ablation System the transbronchial interventional treatment product for lung cancer; Targeted Lung Denervation Radiofrequency Ablation System the self-developed targeted radiofrequency ablation system in China to reduce the risk of acute exacerbation of COPD. Geographically, the company operates in Chinese Mainland; European Union; and Other Regions.
39GF Score
Get the complete analysis for BRNHF
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BRNHF has been successfully added to your 
